Motley Fool22d agobullish
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
531last 24h
2512last 7d
483● bullish (7d)
258● bearish (7d)
197publishers
Motley Fool24d agobullish
2 Beaten-Down Stocks That Still Aren't Worth BuyingYour hard-earned money would be better spent elsewhere.
Motley Fool32d agobullish
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships.
Motley Fool33d agobullish
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.
Motley Fool36d agobullish
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Motley Fool40d agobullish
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider BuyingThese aren't for the faint of heart.
Insider Monkey61d agobullish
Recursion (RXRX) Climbs 9.5% Ahead of Next Week’s Business UpdatesRecursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 9 Stocks Crushing the Market With Surging Returns. Recursion Pharmaceuticals snapped two straight days of losses on Thursday, surging 9.51 percent to close at $3.80 as investors began repositioning portfolios ahead of key business updates next week. In a notice to investors, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) said […]
Motley Fool63d agobullish
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
Motley Fool71d agobullish
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now?The stock looks cheap, but appearances can be deceiving.
Insider Monkey82d agobullish
Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy NowWith a stock price of $3.32, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 10 Unrivaled Penny Stocks to Buy Now. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported first-quarter revenue of $6.47 million on May 7, below analyst consensus estimates of $15.78 million. The company ended the quarter with approximately $665.2 million in cash, cash equivalents, and restricted cash, […]
Insider Monkey90d agobullish
Recursion Pharmaceuticals (RXRX): Best AI Stocks Under $50 to Buy Right NowRecursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion reported significant progress across its AI-driven clinical pipeline for Q1 2026, highlighted by positive early data for its RBM39 degrader, REC-1245. In the Phase 1/2 DAHLIA study, the molecule showed a well-tolerated safety profile […]